Shareholders of MTL Cannabis have delivered a near-unanimous verdict, paving the way for Canopy Growth Corporation to proceed with its planned acquisition. This decisive vote marks a critical step toward establishing a dominant player within the medical cannabis sector.
Overwhelming Shareholder Approval
The shareholder meeting yielded an exceptionally clear mandate. A staggering 99.97% of the votes cast were in favor of the transaction with Canopy Growth. The strong backing is further emphasized by a high voter turnout of approximately 89% among MTL Cannabis shareholders. Even under the stricter regulatory provisions designed to protect minority shareholders—specifically Multilateral Instrument 61-101—support remained remarkably solid at 99.80%. Such a consolidated level of approval is uncommon in merger proceedings and effectively removes potential internal barriers to a smooth integration.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Building a Market Leader
The strategic rationale behind this move centers on achieving market leadership in Canada’s medical cannabis business. Under CEO Luc Mongeau, Canopy Growth’s management aims to merge MTL Cannabis’s specialized cultivation expertise with its own industrial-scale production capabilities. The combined entity is expected not only to solidify its domestic market position but also to enhance competitiveness in regulated international markets. Canopy Growth already maintains operations in Europe and Australia, and the expanded product portfolio is intended to allow for more efficient servicing of these channels.
Next Steps and Timeline
With the shareholder vote successfully concluded, the process now moves to obtaining final court approval and the necessary regulatory clearances. These steps are standard conditions for the transaction’s closing. Management has reaffirmed its existing timeline, anticipating the deal will be finalized before the end of March 2026. Following the official closing, the focus for the subsequent quarter will shift to operational integration and realizing the forecasted synergies between the two companies.
Ad
Canopy Growth Stock: Buy or Sell?! New Canopy Growth Analysis from February 19 delivers the answer:
The latest Canopy Growth figures speak for themselves: Urgent action needed for Canopy Growth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 19.
Canopy Growth: Buy or sell? Read more here...
